Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$272.64 USD
-4.69 (-1.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $272.59 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALNY 272.64 -4.69(-1.69%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Other News for ALNY
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
SIZE: A Good Mid-Cap ETF, Yet Not The Best
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market Potential
Goldman upgrades Alnylam to Buy ahead of 'fundamental re-rating'
Goldman Sachs gets more bullish on Alnylam, upgrades shares